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Cefaclor is an orally absorbed cephalosporin antibiotic chemically and pharmacologically similar to
cephalexin. It appears to be more active than cephalexin against susceptible strains. The in vitro sensitivity of
230 clinical bacterial isolates to cefaclor was studied. Most isolates of S. aureus, K. pneumoniae, E. coli, and
indole negative Proteus species were inhibited at clinically attainable serum and urine concentrations. Like
cephalexin, cefaclor was less active against isolates of Enterobacter species, indole positive Proteus species
and enterococci although many of these isolates were inhibited at concentrations achievable in urine.
INTRODUCTION
Cefaclor, 3-chloro-7-D-(2-phenylglycinamido)-3-cephem-4-carboxilic acid, is a
new cephalosporin antibiotic absorbed by mouth and chemically related to cephal-
exin and cephaloglycin. The methyl group of cephalexin is replaced by a chlorine
group. This report describes the results of in vitro susceptibility studies utilizing this
antibiotic against 230 gram-positive and gram-negative bacterial isolates.
MATERIALS AND METHODS
Antibiotic. Cefaclor monohydrate standard powder and impregnated discs (30 ug)
were supplied by Eli Lilly and Co., Indianapolis, Indiana.
Bacterial Strains. Thirty isolates each of Escherichia coli, Klebsiellapneumoniae,
Enterobacter species, indole positive Proteus, indole negative Proteus, enterococci,
penicillin-resistant Staphylococcus aureus and twenty isolates of penicillin-sensitive
S. aureus were collected from different patients at the Yale-New Haven Hospital. All
isolates were re-identified in our research laboratory. Penicillin susceptibilities of S.
aureus strains were determined by Bauer-Kirby technique [1].
Procedures. For minimal inhibitory concentrations (MIC), twofold serial dilutions
of cefaclor in Mueller-Hinton Broth (MHB) were prepared utilizing an automated
microtitration system (Autotiter III, Canalco Co., Rockville, MD) as previously
reported [2]. Each well was inoculated with a dilution of an 18 hour culture in MHB
such that approximately 103 to 104 colony forming units were delivered to each well,
or 104 to 105 cfu/ml. The final volume in each well was 0.1 ml. The MIC ofcefaclor
for each isolate was defined as the lowest concentration of cefaclor that prevented
growth (detected as turbidity on visual inspection of the microtitration plates) after
18 hours of incubation at 370C. Minimal bactericidal concentrations (MBC) were
determined, after an aliquot from each well was subcultured in antibiotic-free MHB,
and defined as the lowest concentration of cefaclor that prevented growth after
incubation at 37°C for 18 hours. The inhibitory zone around a 30 ug cefaclor
impregnated disc was determined for each isolate on Mueller-Hinton agar and
compared to that isolate's broth dilution susceptibility [1,3].
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RESULTS
Broth Dilution Susceptibility Studies. The MIC and MBC of cefaclor against the
various bacterial isolates are represented in Figs. 1 and 2 as the cumulative percen-
tage of organisms inhibited or killed at each concentration of cefaclor studied. The
most susceptible organisms were S. aureus, K. pneumoniae, E. coli, and the indole
negative Proteus species. More than 90 percent ofthese isolates were inhibited by 32
ug/ml ofcefaclor or less. The most sensitive organisms were the penicillin-sensitive S.
aureus, all of which were inhibited by cefaclor concentrations of 4.0 ug/ml or less.
The enterococcal isolates, indole positive Proteus species and Enterobacter isolates
appeared less sensitive to cefaclor. Only 40 percent ofindole positive Proteus and 40
percent of enterococci were inhibited by 32 ug/ml or less. Enterobacter species were
the least sensitive as only 53 percent were inhibited by concentrations ofcefaclor less
than or equal to 128 ug/ml.
Disc Susceptibility Studies. The diameter of the zone of inhibition of bacterial
growth around a cefaclor (30 ug) impregnated disc is plotted against the MIC of
cefaclor for the gram-negative organisms in Fig. 3 and for the gram-positive organ-
isms in Fig. 4. The 6 mm diameter of the disc is included in the final reading and,
therefore, a zone diameter of 6 mm indicates no inhibition of growth. A zone of
inhibition of greater than 20 mm correlated well with MIC's of 16 ug/ml or less for
the E. coli, K. pneumoniae and indole negative Proteus species tested. Three ofthirty
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FIG. 1. Susceptibility of five species of gram-negative bacteria to increasing concentrations of cefaclor.IN VITRO SUSCEPTIBILITY TO CEFACLOR
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of three species of gram-positive bacteria to increasing concentrations of cefaclor.
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FIG. 3. Correlation of results of 30 ug disc and broth-dilution sensitivities of cefaclor against gram-negative bacteria.
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FIG. 4. Correlation of results of 30 ug disc and broth-dilution sensitivities of cefaclor against gram-positive bacteria.
strains of Enterobacter had no zones ofinhibition despite MIC's equal to or less than
8 ug/ml. Seven isolates of the indole positive Proteus species had MIC's of 8 ug/ml
and zones of inhibition of 29 mm or greater, but for isolates with MIC's of 16 ug/ml
or greater there was no useful correlation with zone size. Of the gram-positive
organisms, only penicillin-sensitive staphylococci showed a relationship between zone
size and MIC. A zone of inhibition of 31 mm or greater correlated with MIC's of 4
ug/ml or less for these organisms.
DISCUSSION
Cefaclor has an antibacterial spectrum similar to that ofcephalexin. In the present
study this antibiotic was bactericidal for most isolates of E. coli, P. mirabilis, and K.
pneumoniae tested. Although conclusions regarding the relative efficacy ofcurrently
available orally absorbed cephalosporins should only be drawn from studies which
compare these agents simultaneously, comparison of results from the present study
with data from previous work with cephalexin done in our laboratory suggests that
cefaclor may be slightly more active than cephalexin against susceptible strains ofE.
coli, K. pneumoniae and Proteus (indole negative and positive species) [3]. Cefaclor
was also effective against most isolates of S. aureus tested, particularly penicillin-
sensitive strains. Although we did not test for methicillin resistance among our
isolates, methicillin-resistant strains of S. aureus are known to be less susceptible to
cefaclor (personal communication, Dr. R. Kammer) as with other cephalosporins.
Like cephalexin, the drug is not as active against isolates of enterococci, indole
positive Proteus and Enterobacter, although several of these isolates were inhibited
by concentrations of cefaclor achievable in urine.
Pharmacokinetic studies in animals have shown that cefaclor is rapidly absorbed
after oral administration and eliminated virtually unchanged in the urine [4]. ThisIN VITRO SUSCEPTIBILITY TO CEFACLOR 469
appears to be true in humans as well. In single-dose studies conducted by Black and
co-workers (presented at the 16th Interscience Conference on Antimicrobial Agents
and Chemotherapy, 27-29 October 1976, Chicago, IL), 250, 500 mg and 1 gram oral
doses of cefaclor gave mean peak plasma concentrations of 6.9, 12.5 and 24 ug/ml
respectively. Sixty to eighty percent ofthe dose was recoverable from the urine in two
to four hours. Currently, available data suggest that cefaclor achieves slightly lower
blood levels than equivalent doses of cephalexin [5,6,7]. However, its greater anti-
bacterial activity and the high levels ofactive drug achieved in the urine may make it
a useful agent in the treatment of urinary tract infections due to susceptible organ-
isms. Further study will be necessary to demonstrate a clinical advantage over
currently available orally absorbed cephalosporins.
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